ROSAIDALIA CARDENAS: Open Payments
NPI 1407420045 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$739 in 33 payments from 12 companies in 2025. Trend: 2023 $15 · 2024 $103 · 2025 $739
Food & beverage: $739
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $160 |
| Teva Pharmaceuticals USA, Inc. | 5 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Janssen Pharmaceuticals, Inc | 3 | $76 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Lundbeck LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Tris Pharma Inc | 1 | $31 |
Products named: REXULTI, UZEDY, CAPLYTA, SPRAVATO, INGREZZA, Auvelity, COBENFY, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
